Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A review of the literature shows that lymphoscintigraphy and sentinel node biopsy are feasible in patients with previous breast and axillary surgery and could be especially warranted because in these patients, lymphatic drainage might not include the axillary basin. We report a case of a woman with recurrent breast cancer after breast-conserving surgery. The patient was found to have metastases in the contralateral intramammary lymph nodes. Demonstrating that such patterns do occur after previous treatment for breast cancer carries implications for the staging and management of these patients.
 ...
PMID:Altered lymphatic drainage after breast-conserving surgery and axillary node dissection: local recurrence with contralateral intramammary nodal metastases. 1738 26

A 32-year-old woman underwent modified radical mastectomy for right breast cancer (invasive ductal carcinoma, f, INF beta, v0, ly1, pT2, pN1, M0, Stage II B ER (+/-), PR (-), Her2 (3+)) in June 2003, and received postoperative systemic adjunctive chemotherapy using epirubicin combined with cyclophosphamide, followed by paclitaxel. In August 2004, after a disease-free interval of 14 months, liver metastasis appeared, and therefore from September 2004, combination chemotherapy with oral capecitabine (2,400 mg/day) and injected trastuzumab (120 mg/week) was started. After 3 cycles, all the metastases responded and this marked response has been maintained for 16 months. This therapy is currently being continued (19 cycles), and no serious side effects have been encountered. Capesitabine and trastuzumab combination therapy is effective for recurrent breast cancer showing overexpression of HER2 and resistance to taxane, and can be considered as a first-line therapy for this purpose. It is anticipated that many cases treated with this regimen will be reported and discussed in the near future.
 ...
PMID:Complete remission of recurrent breast cancer with multiple liver metastases after oral capecitabine and injected trastuzumab. 1769 May 8

The efficacy of hyperthermia and caelyx as single modalities of therapy in progressed and refractory cancer of different primary sites is well known. Nevertheless, it remains question mark whether they can work together to that direction. We have recently published a paper which demonstrates some excellent results in treatment of recurrent breast cancer with hyperthermia in conjunction with caelyx and radiotherapy. The mechanism of action of those different therapeutic options and a review in literature are presented in this paper. Despite the limited number of studies, they all show that the combined treatment is effective and well tolerated. It would be interesting to mention another treatment patent of cancer which can be done by a combination of non-ionizing radiation and androgen deprivation. Also, combined therapy for tumors and tumor metastases comprised administration of integrin ligands and co-therapeutic agents have synergistic efficacy in isolated organ perfusion. Finally, the treatment of solid tumors can be done by glycolytic inhibitors.
 ...
PMID:The efficacy of caelyx and hyperthermia for anticancer treatment. 1822 Oct 68

The purpose of this study was to evaluate the feasibility and utility of a dedicated positron emission tomography (PET)/CT protocol in breast cancer patients. 40 patients with suspected recurrent breast cancer underwent whole-body PET/CT in the supine position (SP) followed by PET/CT of the breasts and axillae in the prone position (PP) using a special positioning aid. PP and SP images were compared in terms of the tumour-to-thoracic-wall distance, tumour-to-skin distance and tumour volume, diameter, density, maximal standardized uptake value (SUV(max)) and localization. The size of axillary areas, the number of intra-axillary lymph nodes, their transverse diameters, their SUV(max) and the number of distant metastases were compared between PP and SP images. Differences were tested for significance using the Student's t-test. All patients tolerated PP imaging well. Five locally recurrent breast cancers were detected, both in the SP and in the PP. Mean tumour-to-thoracic-wall distances (PP, 19 mm; SP, 8 mm; p = 0.003) and tumour-to-skin distances (PP, 10 mm; SP, 7 mm; p = 0.013) were significantly larger in the PP than in the SP. Potential thoracic wall or skin infiltration, as well as quadrant localization, were determined more easily in PP. The axillary area was wider in the PP when compared with SP (PP, 14.4 cm(2); SP, 10.6 cm(2); p<0.001). No other parameters were significantly different. In conclusion, a dedicated whole-body PET/CT examination, including PET/CT mammography, is feasible for clinical practice and may offer important information on the possible infiltration of a breast lesion into the adjacent thoracic wall and skin. Even though the axilla may be delineated more clearly in the PP, there seems to be no benefit with regard to N-staging.
 ...
PMID:Whole-body PET/CT-mammography for staging breast cancer: initial results. 1850 73

Bisphosphonates (BPs) are often used for the treatment of several diseases such as osteoporosis, cancer-associated hypercalcemia, and osteolytic bone metastasis. Recently, there have been reports of osteonecrosis of the jaw (ONJ) in cancer patients whose treatment regimens include BPs. In this case report, we describe complications and treatment of ONJ in a breast cancer patient with bone metastases who received long-term treatment with BPs. A 70-year-old woman underwent modified radical mastectomy on her left breast cancer and received oral 5-fluorouracil derivatives for 2 years in another hospital. Eleven years after the surgery, she came to our hospital complaining of spinalgia and was diagnosed with recurrent breast cancer with multiple metastases to the stomach, liver, multiple lymph nodes, and spine. After surgery for spine metastases, she was given a combination therapy of trastuzumab (initial bolus: 170 mg/body, followed by two or more cycles of 85 mg/body) every week, docetaxel (100 mg/body) every 3 weeks, and BPs (90 mg/body) every 4 weeks. About 1 year and 4 months later, she complained of pain in her right maxilla; biopsy revealed ONJ. Medical oncologists need to recognize ONJ as a serious side effect of BP treatment; dentists and oral and maxillofacial surgeons need to thoroughly consult patients regarding the administration of BPs and have them make an informed consent.
 ...
PMID:A case of osteonecrosis of the jaw in a breast cancer patient with bone metastases receiving long-term treatment with bisphosphonates. 1868 23

We experienced a case of paclitaxel- and trastuzumab-resistant recurrent breast cancer with liver metastases showing significant improvement by S-1. A 76-year-old woman was diagnosed with left breast cancer (T2N1M0, Stage II B). She received total mastectomy and CEF (cyclophosphamide 500 mg/m(2), epirubicin 60 mg/m(2), 5-FU 750 mg/m(2)) as adjuvant chemotherapy in March 2004. But twelve months later, she was referred to our clinic for management of lung and left supraclavicular lymph node metastases. Then weekly paclitaxel (80 mg/m(2)) and trastuzumab were started. After 2 cycles of weekly paclitaxel and trastuzumab treatment, lung and lymph node metastases were reduced and the patient showed a clinical response (CR), so she was treated by trastuzumab only. But seven months later, she was diagnosed as a recurrence of liver metastases. She was treated by combined paclitaxel and trastuzumab again, but liver metastases and tumor marker were progressive. S-1 was administered orally 100 mg/day every day for 4 weeks, followed by a 2-week rest interval as 1 cycle, and trastuzumab was injected at 2 mg/kg/week for every weeks. After 2 courses of the treatment, the level of tumor marker and tumor size of liver metastases were reduced. Only rash (grade 1) was observed during treatment. The treatment of S-1 is thought to be effective for taxane-resistant recurrent breast cancer.
 ...
PMID:[A case of paclitaxel and trastuzumab-resistant recurrent breast cancer with liver metastasis responding to S-1]. 1879 22

A 51-year-old postmenopausal woman was referred to our hospital for treatment of ER-positive recurrent breast cancer. The patient had lung and pleural metastases with pleural effusion from breast cancer. She was treated with anastrozole, a 3rd-generation aromatiase inhibitor. The efficacy of the treatment was definite: the multiple metastatic lung lesions showed a partial response after 5 months' treatment, and reached a complete response after 14 months' treatment. The patient experienced no adverse effects with this therapy. Anastrozole therapy is a useful treatment for postmenopausal woman with ER-positive recurrent breast cancer.
 ...
PMID:[A case of recurrent breast cancer with multiple lung metastases responding to anastrozole monotherapy]. 1893 90

We report a postmenopausal recurrent breast cancer patient with triple negative disease who presented with right recurrent nerve palsy. Nine years previously, she had undergone a mastectomy. FDG-PET scan revealed neck lymph node metastases from the breast cancer. The recurrent nerve palsy was thus considered to have been caused by the lymph node metastases. The patient was orally administered DMpC (doxifluridine, medroxyprogesterone acetate and cyclophosphamide) combination therapy. This resulted in a remarkable response after five months, with the recurrent nerve palsy completely disappearing at six months. No side effects from the treatment were observed. The patient was well and the treatment was being continued without relapse at nine months. Oral anti-cancer treatments such as DMpC appear to have few side effects and might be an effective treatment option for recurrent breast cancer patients with triple negative disease.
 ...
PMID:[Doxifluridine, medroxyprogesterone acetate and cyclophosphamide (DMpC) combination therapy is effective against recurrent triple negative breast cancer--a case report]. 1909 18

A 59-year-old woman underwent modified radical mastectomy for left breast cancer 9 years earlier. This time, a chest wall recurrence was found. A chest CT showed a chest wall tumor and lymph node metastases. PET images showed increased uptake in chest wall tumor and lymph nodes. The serum tumor markers have also elevated. Open biopsy of chest wall tumor was performed, and the tumor was diagnosed as invasive ductal carcinoma[ER(-), Pg R (-), HER2 score(0)]. Combination chemotherapy with capecitabine and docetaxel was initiated. After 7 courses of treatment, a marked response has been seen. Capecitabine and docetaxel combination therapy are considered useful for treatment of triple negative recurrent breast cancer.
 ...
PMID:[A case of triple negative chest wall recurrent breast cancer treated with capecitabine and docetaxel combination therapy (XT therapy)]. 1946 Nov 84

A 60-year-old woman with Stage II, ER-positive, PgR-positive, HER2 (2+) cancer in the right breast underwent right mastectomy with right axillary dissection after chemotherapy with EC followed by docetaxel (DOC) alone. Exemestane was used for postoperative adjuvant treatment. She underwent a right chest wall tumor resection for local recurrence. Hormone therapy was continued with toremifene in place of exemestane. In December 2007, two years after the second surgery, CEA was elevated and PET showed a local recurrence in the right chest wall and metastases to the right axillary nodes and liver. The tumor was ER-positive, PgR-negative and HER2 (3+) at recurrence, and vinorelbine/trastuzumab combination was initiated as first-line chemotherapy for the recurrent lesion and liver metastasis. All lesions in the right chest wall, right axillary nodes and liver disappeared from PET and CT images after five courses of the regimen, resulting in clinical CR. Vinorelbine combined with trastuzumab appears to be a useful therapy for HER2-positive recurrent breast cancer.
 ...
PMID:[A case of recurrent breast cancer responding to vinorelbine/trastuzumab combination therapy]. 2000 69


<< Previous 1 2 3 4 5 6 7 8 9 10